Skip to main content
Clinical Trials/NCT02394431
NCT02394431
Completed
Not Applicable

Added Value of Speckle Tracking in the Evaluation of Patients With Sickle Cell Disease

Brugmann University Hospital1 site in 1 country62 target enrollmentNovember 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sickle Cell Disease
Sponsor
Brugmann University Hospital
Enrollment
62
Locations
1
Primary Endpoint
Myocardiac performance index
Status
Completed
Last Updated
9 years ago

Overview

Brief Summary

Sickle Cell Disease is a serious disease that is life-threatening for patients being homozygous for the SS form or heterozygous for the SC or βthal forms. The CHU Brugmann hospital currently regularly treats about 70 homozygous adult patients and this number is in constant augmentation.

Sickle cell disease patients may develop a cardiomyopathy due to chronic anemia, the haemosiderosis risk or, less frequently, to coronary vaso-occlusive damages.

The hypervolemia in patients with sickle cell disease causes an overestimation of the ejected left ventricular fraction measured by echocardiography, this parameter being very dependent of the blood volume.It has already been shown that the left ventricular ejection fraction was normal in most patients with sickle cell disease, but that its evaluation by parameters independent from the blood volume showed the existence of a dysfunction.

Myocardial strain, as measured by speckle tracking, is a echographic evaluation method of the cardiac function, independent of the blood volume. This technique hasn't been used much in sickle cell disease patients. A study using 3D speckle tracking on a limited number of sickle cell disease patients failed to show a strain anomaly. Moreover, the study highlighted a higher global longitudinal strain in this patient population. The investigators find these data hard to explain and in contradiction with previous studies using other cardiac function evaluation techniques, independent from the blood volume.

The primary goal of this study is thus

  • to study the longitudinal strain by 2D echography
  • to determine if anomalies of the longitudinal strain exist in sickle cell disease patients with a normal ejected left ventricular fraction, compared to a control group of healthy patients.

The secondary goal of this study is to correlate, inside the sickle cell disease group, the possible strain anomalies with biological gravity parameters of the disease.

Registry
clinicaltrials.gov
Start Date
November 2013
End Date
June 2016
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Marielle Morissens

Deputy Head of Clinic

Brugmann University Hospital

Eligibility Criteria

Inclusion Criteria

  • All sickle cell disease patients

Exclusion Criteria

  • Insufficient echogenicity

Outcomes

Primary Outcomes

Myocardiac performance index

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Cardiac diastolic function

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Cardiac tissular doppler

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Cardiac ejection fraction

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Ejection fraction measured by Teicholz and planimety.

Global longitudinal strain

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Global longitudinal strain measured by speckle tracking.

arterial pulmonary hypertension

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

left ventricular hypertrophy

Time Frame: once per year, at the annual medical visit planned according to the standart of care for this pathology

Secondary Outcomes

  • Biological parameters: hemoglobin levels(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Biological parameters: iron levels(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Biological parameters: hematocrit levels(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Biological parameters: ferritin levels(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Clinical parameters: sanguine transfusion numbers(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Clinical parameters: severity of the illness(once per year, at the annual medical visit planned according to the standart of care for this pathology)
  • Biological parameters: red cells count(once per year, at the annual medical visit planned according to the standart of care for this pathology)

Study Sites (1)

Loading locations...

Similar Trials